2029049-79-2
|
|
|
- CAS号:
- 2029049-79-2
- 英文名:
- ml390
- 英文别名:
- ml390;(R)-N-(3-Oxo-3-((1,2,3,4-tetrahydronaphthalen-1-yl)amino)propyl)-4-(trifluoromethoxy)benzamide;Benzamide, N-[3-oxo-3-[[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]propyl]-4-(trifluoromethoxy)-;ER-HoxA9,Dihydroorotate Dehydrogenase,inhibit,AML,ML 390,differentiatio,U937,DHODH,ML390,myeloid,ML-390,Inhibitor,THP1
- 中文名:
- 2029049-79-2
- 中文别名:
- 化合物ML390;优选]ML390;(R)-N-(3-氧代-3-((1,2,3,4-四氢萘-1-基)氨基)丙基)-4-三氟甲氧基)苯甲酰胺
- CBNumber:
- CB43145908
- 分子式:
- C21H21F3N2O3
- 分子量:
- 406.4
- MOL File:
- 2029049-79-2.mol
|
|
|
2029049-79-2化学性质
-
沸点:
-
599.7±50.0 °C(Predicted)
-
|
-
密度:
-
1.31±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
≥40.6 mg/mL in DMSO; insoluble in H2O; ≥17.47 mg/mL in EtOH
-
|
-
形态:
-
solid
-
|
-
酸度系数(pKa):
-
13.65±0.46(Predicted)
-
|
2029049-79-2性质、用途与生产工艺
ML390 是一种有效的二氢乳清酸脱氢酶 (DHODH) 抑制剂。ML390 是骨髓分化的诱导剂，并在鼠 (ER-HoxA9) 和人 (U937 and THP1) 急性髓细胞性白血病 (AML) 细胞中引起骨髓分化。
ML390 is active with an ED
50
of ~2 μM in murine and human AML cell lines. In vitro, treatment of Lys-GFP-ER-HoxA9 cells with ML390 for 48 hr inhibits DHODH activity, leading to the dramatic (>500-fold) accumulation of the upstream metabolite DHO and the depletion of uridine and other downstream metabolites.
2029049-79-2
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-100688 | 2029049-79-2
ML390 | 2029049-79-2 | 5mg | 1500元 |
| 2024/04/30 | HY-100688 | 2029049-79-2
ML390 | 2029049-79-2 | 10mM * 1mLin DMSO | 1650元 |
2029049-79-2, 2029049-79-2 相关搜索:
- 药靶配体
- 优选]ML390
- (R)-N-(3-氧代-3-((1,2,3,4-四氢萘-1-基)氨基)丙基)-4-三氟甲氧基)苯甲酰胺
- 化合物ML390
- 2029049-79-2
- (R)-N-(3-Oxo-3-((1,2,3,4-tetrahydronaphthalen-1-yl)amino)propyl)-4-(trifluoromethoxy)benzamide
- ER-HoxA9,Dihydroorotate Dehydrogenase,inhibit,AML,ML 390,differentiatio,U937,DHODH,ML390,myeloid,ML-390,Inhibitor,THP1
- Benzamide, N-[3-oxo-3-[[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]propyl]-4-(trifluoromethoxy)-
- ml390